Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F21%3AN0000240" target="_blank" >RIV/00098892:_____/21:N0000240 - isvavai.cz</a>
Result on the web
<a href="https://biomed.papers.upol.cz/artkey/bio-202104-0009_beta-blockers-utilization-in-heart-failure-patients-sub-analysis-of-a-nation-wide-population-based-study-in-th.php?back=%2Fsearch.php%3Fquery%3DBeta-blockers%25A0utilization%25A0in%25A0heart%25A0failure%25A0patients%253A%25A0Sub-analysis%25A0of%25A0a%25A0nation-wide%25A0population-based%25A0study%25A0in%25A0the%25A0Czech%25A0Republic%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26spage%3D30" target="_blank" >https://biomed.papers.upol.cz/artkey/bio-202104-0009_beta-blockers-utilization-in-heart-failure-patients-sub-analysis-of-a-nation-wide-population-based-study-in-th.php?back=%2Fsearch.php%3Fquery%3DBeta-blockers%25A0utilization%25A0in%25A0heart%25A0failure%25A0patients%253A%25A0Sub-analysis%25A0of%25A0a%25A0nation-wide%25A0population-based%25A0study%25A0in%25A0the%25A0Czech%25A0Republic%2Bin%253Aauth%2Bname%2Bkey%2Babstr%26sfrom%3D0%26spage%3D30</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.5507/bp.2020.057" target="_blank" >10.5507/bp.2020.057</a>
Alternative languages
Result language
angličtina
Original language name
Beta-blockers utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic
Original language description
Aims. Sub-analysis of a retrospective nation-wide observational analysis of heart failure (HF) epidemiology reported to the Czech National Registry of Reimbursed Health Services between 2012 and 2018 aimed at beta-blockers (BBs) utilization. Methods and Results. The beta-blockers were generally used in 81.8% of all patients treated for HF in 2012 (n=52 140); 81.8% in 2013 (n=53 058); 83.1% in 2014 (n=56 221); 82.1% in 2015 (n=57 421); 83.3% in 2016 (n=59 187); 82.2% in 2017 (60 058) and in 81.4% in 2018 (n=60 966). In 2018, the majority of patients treated for HF were prescribed metoprolol (22 974; 30.7%) and bisoprolol (21 001; 28%). Carvedilol was prescribed in 7 331 patients treated for HF (9.8%), nebivolol in 5 392 HF patients. Despite its primary indication, betaxolol was used in 2 341 patients treated for HF (3.1%). All other beta-blockers were used in less than 1% of HF patients. In some of the mostly used BBs, their prescription in patients treated for HF changed in the last years (metoprolol 32.4% in 2012, 30.7% in 2018; bisoprolol 20.3% in 2012, 28% in 2018; carvedilol 18.3% in 2012, 9.8% in 2018; nebivolol 2.5% in 2012, 7.2% in 2018; betaxolol 4.2% in 2012, 3.1% in 2018). Conclusion. In an analysis of beta-blockers utilization in all patients treated for heart failure in the given year in the whole country, we have found only slightly lower amount of drug prescription in comparison with specific heart failure registries. This indicates a good translation of current standard of care into common clinical practice. Metoprolol remained the mostly prescribed drug. The prescription of bisoprolol and nebivolol has increased at the expense of carvedilol.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedical Papers-Olomouc
ISSN
1213-8118
e-ISSN
1804-7521
Volume of the periodical
165
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
6
Pages from-to
402-407
UT code for WoS article
000722224100009
EID of the result in the Scopus database
2-s2.0-85120156896